Clinical Trials Logo

Disease Progression clinical trials

View clinical trials related to Disease Progression.

Filter by:

NCT ID: NCT00988052 Terminated - Clinical trials for Relapsing Multiple Sclerosis

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Start date: November 10, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.

NCT ID: NCT00899353 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

Start date: August 2008
Phase: Phase 2
Study type: Interventional

Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require treatment. The primary aim of the study is to determine if the Omega 3 supplementation will help prevent or delay progression of the disease to a stage that requires treatment.

NCT ID: NCT00811967 Terminated - Liver Cirrhosis Clinical Trials

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Start date: February 2003
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the superiority of treatment with PegIntron and Rebetol over no antiviral therapy (control group) in subjects with chronic hepatitis C and type C compensated cirrhosis. Subjects will be randomized in a ratio of 2:1 (Treatment Arm to Control Arm). Subjects in the Treatment Arm will receive combination therapy with PegIntron and Rebetol for 48 weeks; then will enter a 24-week post-treatment Follow-up. Subjects who have detectable Hepatitis C Virus-RNA at Treatment Week 24 will discontinue treatment and enter Follow-up.

NCT ID: NCT00338091 Terminated - Proteinuria Clinical Trials

Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency

Start date: January 2002
Phase: N/A
Study type: Interventional

The primary goal of the trial was to evaluate whether the optimal antiproteinuric doses of benazepril (an ACE inhibitor) or losartan (an ARB), as compared with their conventional doses, can safely improve the long-term renal outcome in nondiabetic patients with proteinuria and chronic renal insufficiency. The second aim was to compare the long-term renal protection between benazepril and losartan at similar clinical setting.